Bundesinstitut für Arzneimittel und Medizinprodukte Pt WHO-consultant 1 WHO Training Workshop on Pharmaceutical Quality, Good Manufacturing Practice &

Slides:



Advertisements
Similar presentations
Timelines Trust informed June 2007
Advertisements

Tips to a Successful Monitoring Visit
PRINCIPLES OF A CALIBRATION MANAGEMENT SYSTEM
Good Clinical Practices
The New GMP Annex 11 and Chapter 4 Deadline for coming into operation: 30 June 2011.
Presentation of BE data in a product dossier Drs. Jan Welink Training workshop: Training of BE assessors, Kiev, October 2009.
Special populations- What makes them so special? AGAH Association for Applied Human Pharmacology Annual meeting 2004 Berlin 29. Februar 2004 Birka Lehmann.
HOT TOPICS ARCHIVING OR HOW NOT TO DUMP YOUR RUBBISH!
Clinical QA Data Audits A GCP Point of View Linda Del Paggio GCP Compliance BioBridges, LLC.
SOP Melody Lin, Ph.D. Deputy Director, Office for Human Research Protections Director, International Activities Santiago, Chile August.
GMP Document and Record Retention
Good Manufacturing Practices Guilin, PRC Dr AJ van Zyl for Quality Assurance and Safety: Medicines Medicines Policy and Standards Health Technology and.
1st Global QA Conference & 21st SQA Annual Meeting Falcon Consulting Group, LLC 1 Phase I Clinical Study Audits “A Deeper Scrutiny” Cheryl J. Priest, R.N.
GCP compliance for GenISIS  This presentation is intended for clinical staff involved in recruiting patients to the GenISIS (Genetics of Influenza Susceptibility.
ICH GCP, the MHRA and PATHOLOGY PATHOLOGY QUALITY ASSURANCE Rob Wosley MRQA SEPTEMBER 2009.
Developed by Klinikos; Roy Fraser (2012) Investigator Study File
Managing Sponsorship Research Services University of Oxford.
Quality Assurance/Quality Control Policy
Introduction into the workshop Drs. Jan Welink Training workshop: Training of BE assessors, Kiev, October 2009.
Roles and Responsibilities
Management of Change Control. Overview Changes – Good or bad? Forced or voluntary? The Importance of Change Control Major Changes to both legacy company.
Personnel Basic Principles of GMP Workshop on
1 GMP issues in Q assessment Wondiyfraw Worku Assessor 6 th CPH assessment training workshop, May 2014.
Good Clinical Practice GCP
World Health Organization
Federal Institute for Drugs and Medical Devices The BfArM is a Federal Institute within the portfolio of the Federal Ministry of Health 1 Quality of Bioequivalence.
Good Laboratory Practice
Regulatory Overview.
Quality Assurance in Bio-availability / Bio-equivalence studies. DR
Assessment of Interchangeable Multisource Medicines Quality of BE Data Dr. Henrike Potthast Training workshop: Assessment of Interchangeable.
Recapture of Day 1 Suchart Chongprasert, Ph.D. Food and Drug Administration “Practical Aspects in Performing Clinical and Bioanalytical Parts in BA/BE.
Good Clinical Practice (GCP)- An introduction Dr Noor Ibrahim Mohamed Sakian.
Target Institute of Medical Education & Research (TIMER) Provides Clinical Research services to Pharmaceutical, Biotechnology product companies right.
Regulatory Authority Governing Clinical Trials Anthony J. Minisi, MD Director, Cardiology Fellowship Program.
CONFIDENTIAL Copyright  Cato Research Ltd. 1 How do clinical trials relate to the MRF1? Lynn Katsoulis SAPPRA 23 March 2007.
Elements of Clinical Trial Quality Assurance Regulatory Coordinator –SCTR SUCCESS Center QA Monitor – NIDA Clinical Trials Network Stephanie Gentilin,
PERSONNEL TRAINING IN BIOANALYSIS DR. SHIVPRAKASH MANAGING DIRECTOR SYNCHRON RESEARCH SERVICES PVT. LTD., INDIA.
Good Laboratory Practice CFR 21 Part 58 A Review for OCRA US RAC Study Group September 2005 Ginger Clasby, MS Promedica International
Joint Research & Enterprise Office Training The team, the procedures, the monitor and the Sponsor Lucy H H Parker Clinical Research Governance Manager.
University of Miami Office of Research Compliance Assessment Lynn E. Smith, JD, CIM, CIP Johanna Stamates, RN, BA, CCRC With assistance from Elizabeth.
WHO Workshop on Assessment of Bioequivalence Data Addis Ababa, 31. August – 3. September Frequent Deficiencies Dr. Henrike Potthast
CLINICAL TRIALS – PHASE III. What are phase III trials  Confirmatory phase (Therapeutic confirmatory trial)  Trials are done to obtain sufficient evidence.
The Global Health Network Marijke Geldenhuys 19 September 2014 Adhering to the GCP Principles.. what does that even mean?
Important informations
ISO / IEC : 2012 Conformity assessment – Requirements for the operation of various types of bodies performing inspection.
Quality of Bioequivalence Data Alfredo García - Arieta Training workshop: Training of BE assessors, Kiev, October 2009.
UC DAVIS OFFICE OF RESEARCH Overview of Good Clinical Practices (GCP) Investigator and Study Team Responsibilities Miles McFann IRB Administration Training.
Basic Principles of GMP
Training Workshop: Training of BE Assessors Kiev, October 2009 Frequent Deficiencies Dr. Henrike Potthast Training workshop: Training.
Molecule-to-Market-Place Quality
30/02/2008 Dept. of Pharmaceutics 1 Salient Features of Quality Assurance Dr. Basavaraj K. Nanjwade M.Pharm., Ph.D Associate Professor Department of Pharmaceutics.
Federal Institute for Drugs and Medical Devices The BfArM is a Federal Institute within the portfolio of the Federal Ministry of Health 1 Statistical Considerations.
Lifespan GOOD CLINICAL PRACTICE Record Management GCP May 2005.
Korea Food & Drug Administration Deputy director Kwang-Soo Joo Korea FDA Sep. 29, 2000 : Korean Good Clinical Practice & Relative Guidelines How to Manage.
Good Laboratory Practice - general information Pirkko Puranen Senior Inspector, Ph.D. Inspectorate.
Good Laboratory Practice
Responsibilities of Test Facility Management, Study Director, Principal Investigator and Study Personnel G. Jacobs Belgian GLP Monitorate Zagreb, 17 December.
The First Conference for Medicines Regulatory Authorities In Sudan and Neighboring Countries Khartoum December 2014 Alain PRAT, Technical Officer,
GCP (GOOD CLINICAL PRACTISE)
Responsibilities of Sponsor, Investigator and Monitor
Tanzania, August 2006 Dr. Barbara Sterzik, BfArM, Bonn 1 Bioequivalence dossier requirements for the prequalification project WHO Training Workshop.
Responsibilities of Sponsor, Investigator and Monitor
נמטוציטים משושנת ים Eli. S Lec. No.2.
ISO/IEC
LNH Pharma A Trusted Partner.
Good Clinical Practice
UK Legal Requirement for Notification of Serious Breaches of Good Clinical Practice or The Trial Protocol John Poland, PhD Senior Director, Regulatory.
Good Laboratory Practices
Good Laboratory Practice CFR 21 Part 58
S A Overarching SOPs Funding Secured Training Records
Presentation transcript:

Bundesinstitut für Arzneimittel und Medizinprodukte Pt WHO-consultant 1 WHO Training Workshop on Pharmaceutical Quality, Good Manufacturing Practice & Bioequivalence Quality of BE Studies Kiev, October 3-7, 2005 Dr. H. Potthast

Bundesinstitut für Arzneimittel und Medizinprodukte Pt WHO-consultant 2 Regulations  ICH-GCP guideline (CPMP/ICH/135/95)  Guide to GMP incl. Annex 13  WHO documents  EU “Note for Guidance on the Investigation of Bioavailability and Bioequivalence” CPMP/EWP/QWP/1401/98, related guidances and others

Bundesinstitut für Arzneimittel und Medizinprodukte Pt WHO-consultant 3 Legal Basis  acc. to e.g. Directive 2001/20/EC: “The verification of compliance with the standards of good clinical practice and the need to subject data, information and documents to inspection in order to confirm that they have been properly generated, recorded and reported are essential in order to justify the involvement of human subjects in clinical trials.”  finding/definition of inspection triggers

Bundesinstitut für Arzneimittel und Medizinprodukte Pt WHO-consultant 4 Assessment Process  General Requirements  BE studies as a substitute for clinical and preclinical data  Quality of the BE study is of decisive importance for approval of the product

Bundesinstitut für Arzneimittel und Medizinprodukte Pt WHO-consultant 5 Inspection Triggers  Environmental triggers - examples  random selection acc. to annual inspection program  information from other regulatory authorities F type of product (e.g. particular narrow therap. range) F lack of previous inspections for product/applicant/location F……  general indication for inspection

Bundesinstitut für Arzneimittel und Medizinprodukte Pt WHO-consultant 6 Inspection Triggers  Early phase triggers - examples  history of (serious) problems for sponsor, CRO, sites, labs Finvolvement of clinical site/CRO/labs in many studies Fbusiness related issues (e.g. bankruptcy, mergers) F lack of audit certificates F…..  Still general indication without direct implication of trial data

Bundesinstitut für Arzneimittel und Medizinprodukte Pt WHO-consultant 7 Inspection Triggers  Evaluation phase triggers - examples  protocol gives incomplete/illogical information Fnumerous protocol violations Funsatisfactory explanation for protocol violations F data too clean/too messy Fnumber of missing values/drop outs/nds….  Findings due to knowledge from literature and other studies; type of generic product already known

Bundesinstitut für Arzneimittel und Medizinprodukte Pt WHO-consultant 8 Inspection Triggers  Evaluation phase triggers – contd.  conflicting (PK-)results as compared to known data Finsufficient documentation (clinic, analytics, statistics) Fmissing documentation F implausibility/inconsistency of clinical or analytical data (e.g. long half-life – short wash-out – no carry-over?!) Fdoubtful statistics or change in the analysis….

Bundesinstitut für Arzneimittel und Medizinprodukte Pt WHO-consultant 9 Inspection Triggers  Information exchange Fevaluation of triggers positive (negative – non serious/’formal’) negative – serious  request/list of questions  EMEA inspection data base since 2004

Bundesinstitut für Arzneimittel und Medizinprodukte Pt WHO-consultant 10 Inspections  Evaluation/Inspection based on source data/raw data e.g. Fprint outs of chromatograms  signed CRFs  analytic protocols Ftime schedules Flist of providers …….

Bundesinstitut für Arzneimittel und Medizinprodukte Pt WHO-consultant 11 Inspections Data verification & QA issues  GCP compliance statement available?  audit/monitoring reports available?  protocol valid, i.e. signed (incl. amendments)?  was the protocol followed?  genuine study subjects/volunteers?  archiving of source/raw data?  violations of the protocol justified?

Bundesinstitut für Arzneimittel und Medizinprodukte Pt WHO-consultant 12 Inspections Data verification & QA issues ctd.  excluded subjects - traceable?  consistent trial results?  final responsibility of investigators (signing)?  source of investigative products?  batch information available?  handling of investigative products?

Bundesinstitut für Arzneimittel und Medizinprodukte Pt WHO-consultant 13 Inspections Data verification & QA issues ctd.  validation of bioanalytical method?  timing  validation characteristics  adherence to GLP  SOPs available……  calibrated equipment?  computer systems????  archiving of bioanalytical raw data

Bundesinstitut für Arzneimittel und Medizinprodukte Pt WHO-consultant 14 Inspections Data verification & QA issues ctd.  statistical plan adhered to?  transfer of analytical data to statistics  main pharmacokinetic characteristics  method of determination  nd values considered?  statistical outcome and conclusions consistent?  archiving of statistical raw data

Bundesinstitut für Arzneimittel und Medizinprodukte Pt WHO-consultant 15 Inspections Regulatory & ethical issues  independent ethics committee?  ethical approval based on appropriate documentation?  protocol  amendments  investigators brochure; SPC  subjects information informed consent  approval of competent authority in time?  subjects from vulnerable populations?  signing of subjects available?

Bundesinstitut für Arzneimittel und Medizinprodukte Pt WHO-consultant 16 Inspections Regulatory & ethical issues ctd.  insurance of subjects adequate?  adequately instructed personnel?  investigators  technicians  suppliers…..  safety evaluation assured throughout the trial?  retention samples sufficient?  storage of retention samples?

Bundesinstitut für Arzneimittel und Medizinprodukte Pt WHO-consultant 17 Inspections FINDINGS  …  ….  …

Bundesinstitut für Arzneimittel und Medizinprodukte Pt WHO-consultant 18 Inspections A Matter of TRUST!